Table 2.
Evaluation of penile erectile function, and prevalence of mild, mild–moderate and moderate ED assessed by IIEF-6 questionnairea, and prevalence of mild–moderate and severe vasculogenic ED assessed at dynamic PDUb, at baseline (T0) and after 90 days (T1), in l-arginine and placebo groups, in the overall cohort
| l-arginine T0 (N = 51) | l-arginine T1 (N = 50) | p value | Placebo T0 (N = 47) | Placebo T1 (N = 45) | p value | |
|---|---|---|---|---|---|---|
| IIEF-6 score | 20 (16–22) | 24 (19–25.3) | < 0.0001 | 20 (17–22) | 20 (17–22) | NS |
| PSV (cm/s) | 25.9 (24.6–28) | 30.5 (23.4–34.3) | < 0.0001 | 27.1 (24.2–29.6) | 27.1 (24.5–29.6) | NS |
| Mild EDa | 14/51 (27.45%) | 18/50 (36%) | NS | 13/47 (27.66%) | 11/45 (24.44%) | NS |
| Mild–moderate EDa | 21/51 (41.18%) | 16/50 (32%) | NS | 29/47 (61.7%)§ | 23/45 (51.11%) | NS |
| Moderate EDa | 16/51 (31.37%) | 4/50 (8%) | 0.005 | 5/47 (10.64%)° | 10/45 (22.22%) | NS |
| No EDa | 0/51 (0%) | 12/50 (24%) | 0.0001 | 0/47 (0%) | 1/45 (2.23%) | NS |
| Mild–moderate vasculogenic EDb | 33/51 (64.71%) | 22/50 (44%) | 0.047 | 35/47 (74.47%) | 27/45 (60%) | NS |
| Severe vasculogenic EDb | 18/51 (35.29%) | 18/50 (36%) | NS | 12/47 (25.53%) | 14/45 (31.11%) | NS |
| No EDb | 0/51 (0%) | 10/50 (20%) | < 0.001 | 0/47 (0%) | 4/45 (8.89%) | NS |
Values expressed as median with interquartile range (25°–75° centiles), or number of cases (%)
PSV cavernous arteries peak systolic flow velocity
§p = 0.047 compared to T0 l-arginine, °p = 0.015 compared to T0 l-arginine